Edition:
India

Biocartis Group NV (BCART.BR)

BCART.BR on Brussels Stock Exchange

11.38EUR
20 Nov 2018
Change (% chg)

-- (--)
Prev Close
€11.38
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
66,024
52-wk High
€15.00
52-wk Low
€10.54

Latest Key Developments (Source: Significant Developments)

Biocartis Group Announces Positive Study Results On Idylla Msi And Ras Liquid Biopsy Tests
Friday, 19 Oct 2018 

Oct 19 (Reuters) - BIOCARTIS GROUP NV ::RESULTS OF STUDY SHOWED IDYLLA(TM) LIQUID BIOPSY CTRAS-BRAF TESTS CAN PREDICT TREATMENT OUTCOME IN PATIENTS WITH MCRC.SECOND STUDY REVEALED POSITIVE PERFORMANCE OF PROTOTYPE IDYLLA(TM) MSI TEST BASED ON CONCORDANCE COMPARED TO OTHER TESTING METHODS FREQUENTLY USED.CONCORDANCE OF 98.7% WAS ACHIEVED WITH PROMEGA MSI ANALYSIS SYSTEM AND A CONCORDANCE OF 97.6% WITH IMMUNOHISTOCHEMICAL (IHC) ANALYSIS.SECOND STUDY DEMONSTRATES ROBUSTNESS OF IDYLLA(TM) MSI ASSAY, WHICH PROVIDES INFORMATION ON MSI STATUS OF TUMOR IN RAPID AND EASY WAY.THE STUDIES ON IDYLLA(TM) MSI AND RAS LIQUID BIOPSY TESTS TO BE PRESENTED AT ESMO CONGRESS.  Full Article

Biocartis Announces 2018 Half-Year Results On 6 September 2018
Thursday, 30 Aug 2018 

Aug 30 (Reuters) - Biocartis Group NV ::REG-BIOCARTIS GROUP NV: BIOCARTIS ANNOUNCES 2018 HALF-YEAR RESULTS ON 6 SEPTEMBER 2018.  Full Article

Biocartis Obtains Exclusive Worldwide License Rights For EGFR Ectodomain Mutations
Tuesday, 28 Aug 2018 

Aug 28 (Reuters) - BIOCARTIS GROUP NV ::REG-BIOCARTIS GROUP NV: BIOCARTIS OBTAINS EXCLUSIVE WORLDWIDE LICENSE RIGHTS FOR EGFR ECTODOMAIN MUTATIONS DETERMINING RESPONSE TO TARGETED COLORECTAL CANCER THERAPY.IS ENTITLED TO SUBLICENSE LICENSED RIGHTS TO THIRD PARTIES.NEW AGREEMENT IS CONVERSION OF EXISTING AGREEMENTS WITH HOSPITAL DEL MAR AND INVENTORS DR. BARDELLI AND DR. ARENA FROM UNIVERSITY OF TORINO.  Full Article

Biocartis Group Launches Innovative Idylla Msi Assay
Tuesday, 17 Jul 2018 

July 17 (Reuters) - Biocartis Group NV ::REG-BIOCARTIS GROUP NV: BIOCARTIS LAUNCHES INNOVATIVE IDYLLA(TM) MSI ASSAY.IDYLLA MSI ASSAY PROVIDES INFORMATION ON MSI STATUS (I.E. MSI-HIGH OR MICROSATELLITE STABLE) OF A TUMOR WITHIN APPROXIMATELY 150 MIN FROM JUST ONE SLICE OF FFPE TUMOR TISSUE, WITHOUT REQUIRING A REFERENCE SAMPLE.  Full Article

Biocartis' Idylla EGFR Mutation Test Able To Produce Result In 80 Percent Of Failed Next Generation Sequencing Lung Cancer Tests, According To Study
Monday, 28 May 2018 

May 28 (Reuters) - Biocartis Group NV ::STUDY DEMONSTRATES ABILITY OF IDYLLA(TM) EGFR MUTATION TEST TO PRODUCE A RESULT IN 80% OF FAILED NEXT GENERATION SEQUENCING LUNG CANCER TESTS.  Full Article

Biocartis & Immunexpress Partnership For A Sepsis Host Immune Response Test
Wednesday, 24 Jan 2018 

Jan 24 (Reuters) - BIOCARTIS GROUP NV ::BIOCARTIS & IMMUNEXPRESS SIGN PARTNERSHIP FOR A SEPSIS HOST IMMUNE RESPONSE TEST ON THE IDYLLA™ PLATFORM.AGREEMENT TO DEVELOP, COMMERCIALIZE OF IMMUNEXPRESS’ SEPTICYPTE TEST FOR USE ON CO'S SAMPLETO-RESULT IDYLLA PLATFORM‍​.  Full Article

Biocartis And Amgen Sign New Agreement
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Biocartis Group Nv ::REG-BIOCARTIS GROUP NV: BIOCARTIS AND AMGEN SIGN NEW COMPANION DIAGNOSTIC AGREEMENT FOR NOVEL ONCOLOGY COMPOUND.AGREEMENT AIMED AT DEVELOPMENT OF IDYLLA(TM) CDX BIOMARKER TESTS .FINANCIAL DETAILS ON NEW CDX AGREEMENT WITH AMGEN ARE NOT DISCLOSED..  Full Article

Biocartis And Amgen Sign Companion Diagnostic Agreement For Idylla(Tm) RAS Biomarker Tests
Monday, 4 Dec 2017 

Dec 4 (Reuters) - BIOCARTIS GROUP NV ::BIOCARTIS AND AMGEN <<>> SIGN COMPANION DIAGNOSTIC AGREEMENT FOR IDYLLA(TM) RAS BIOMARKER TESTS.BIOCARTIS -WILL PURSUE A PREMARKET APPROVAL FOR IDYLLA KRAS MUTATION TEST AND IDYLLA NRAS-BRAF MUTATION TEST WITH FDA​.‍AMGEN WILL PROVIDE FINANCIAL AND OPERATIONAL SUPPORT TO BIOCARTIS FOR PMA PROCESS​.‍AIM OF AGREEMENT IS TO REGISTER IDYLLA RAS BIOMARKER TESTS WITH US FDA AS COMPANION DIAGNOSTIC TEST FOR AMGEN'S DRUG VECTIBIX(PANITUMUMAB).​.  Full Article

Bookrunner says Biocartis Group deal upsized to 80 mln euros From 60 mln euros base deal size‍​
Wednesday, 29 Nov 2017 

Nov 28 (Reuters) - :BLOCK TRADE- BIOCARTIS GROUP NV: BOOKRUNNER SAYS DEAL UPSIZED TO 80 MILLION EUROS FROM 60 MILLION EUROS BASE DEAL SIZE‍​.BLOCK TRADE- BIOCARTIS GROUP NV: BOOKRUNNER SAYS BOOKS ARE OVERSUBSCRIBED ON THE 80 MILLION EUROS DEAL SIZE.BLOCK TRADE- BIOCARTIS GROUP NV: BOOKRUNNER SAYS PRICE GUIDANCE OF 12.50 EUROS PER SHARE.BLOCK TRADE- BIOCARTIS GROUP NV: BOOKRUNNER SAYS BOOKS CLOSE AT 1830 UK TIME.  Full Article

Biocartis Share Offering Of Up To About 8.9 mln Shares ‍​- bookrunner
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Biocartis Group Nv's Bookrunner: :SAYS OFFERING OF UP TO ABOUT 8.9 MILLION SHARES ‍​.SAYS OFFERING DEAL SIZE ABOUT 60 MILLION EUROS‍​.  Full Article